The definitive agreement encompasses a suite of established diagnostic products, including the Prequel, Foresight, SneakPeek, and FirstGene tests. For Myriad, the divestiture is the outcome of a comprehensive strategic review aimed at bolstering profitability and strengthening the company's balance sheet. By shedding this segment, the firm anticipates a more streamlined path toward long-term revenue growth.
In section Market Quotes
Labcorp Acquires Myriad Genetics Prenatal Unit for $210 Million
A 19% surge in Myriad Genetics shares followed the announcement that the company is offloading its prenatal health testing division to Labcorp. The $210 million cash deal marks a significant shift for both firms as Myriad seeks to sharpen its financial focus while Labcorp expands its specialized diagnostic footprint.
Labcorp views the acquisition as a tactical move to scale its specialty testing portfolio. The company projects the integration will generate approximately $160 million in additional revenue, with expectations for a modest lift to earnings within the first year of operation. The transaction price includes the base cash payment plus the value of existing inventory, with both parties targeting an exit from the prenatal space for Myriad and a consolidation of diagnostic assets for Labcorp.
Comments (0)
No comments yet. Be the first!